1. Pink Sheet
  2. >>Compliance

Perrigo Eyes $115 Bil. Worth Of Rx-To-OTC Switches On The Horizon

 
• By Dan Schiff

The private labeler sees about $115 billion worth of branded Rx products with potential to switch OTC, including statins and longer-shot switches for diabetes, hypertension and topical steroid drugs. Perrigo’s shorter-term pipeline includes equivalents of proton pump inhibitors Nexium, Protonix and Aciphex.

Perrigo Co. PLC sees long-term Rx-to-OTC switch potential for about $115 billion worth of branded prescription products that the company would mine for its own private-label versions.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Distribution/Supply Chain

More from Compliance